Mifepristone (RU 486) in Cushing's syndrome

European Journal of Endocrinology

Volumn 157, Issue 5, 2007, Pages 561-569

  Johanssen, Sarah ^a   Allolio, Bruno ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; HYDROCORTISONE; KETOCONAZOLE; MIFEPRISTONE; MITOTANE; PLACEBO; PROSTAGLANDIN DERIVATIVE; SPIRONOLACTONE; SULPROSTONE;

ACTH SECRETING ADENOMA; ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL INSUFFICIENCY; ADRENALECTOMY; AMENORRHEA; ANDROGEN BLOOD LEVEL; ANOREXIA; BINDING AFFINITY; BREAST CANCER; CLINICAL TRIAL; CORTICOTROPIN BLOOD LEVEL; CUSHING SYNDROME; DIZZINESS; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIOSIS; ENDOMETRIUM HYPERPLASIA; FATIGUE; GRAND MAL SEIZURE; GYNECOMASTIA; HASHIMOTO DISEASE; HOT FLUSH; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCORTISOLISM; HYPOKALEMIA; HYPOTENSION; HYPOTHYROIDISM; IMPOTENCE; LIBIDO DISORDER; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MENINGIOMA; MYOMA; NAUSEA; NONHUMAN; PLASMA HALF LIFE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR BLOCKING; REVIEW; SIDE EFFECT; THYROTROPIN BLOOD LEVEL; VAGINA BLEEDING; WEIGHT REDUCTION;

ANIMALS; CUSHING SYNDROME; HUMANS; MIFEPRISTONE;

EID: 36549032804     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0458     Document Type: Review

References (50)

1. Ulmann A, Teutsch G & Philibert D. RU 486. Scientific American 1990 262 42-48.
2. Bertagna X, Bertagna C, Luton JP. Husson JM & Girard F. The new steroid analog RU 486 inhibits glucocorticoid action in man. Journal of Clinical Endocrinology and Metabolism 1984 59 25-28.
3. Kettel LM. Clinical applications of the antiprogestins. Clinical Obstetrics and Gynecology 1995 38 921-934.
4. Foldesi I, Falkay G & Kovacs L. Determination of RU 486 (mifepristone) in blood by radioreceptorassay; a pharmacokinetic study. Contraception 1996 54 27-32.
5. Kekkonen R, Heikinheimo O, Mandelin E & Lahteenmaki P. Pharmacokinetics of mifepristone after low oral doses. Contraception 1996 54 229-234.
6. Lähteenmäki P, Heikinheimo O, Croxatto H, Spitz IM, Shoupe D, Birgerson L & Luukkainen T. Pharmacokinetics and metabolism of RU 486. Journal of Steroid Biochemistry 1987 27 859-863.
7. Heikinheimo O, Kontula. K, Croxatto H, Spitz I, Luukkainen T & Lahteenmaki P. Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. Journal of Steroid Biochemistry 1987 26 279-284.
8. Heikinheimo O, Kekkonen R & Lahteemnaki P. The pharmacokinetics of mifepristone m humans reveal insights into differential mechanisms of antiprogestin action. Contraception 2003 68 421-426.
9. Heikinheimo O. Clinical pharmacokinetics of mifepristone. Clinical Pharmacokinetics 1997 33 7-17.
10. Kawai S, Nieman LK, Brandon DD, Udelsman R, Loriaux DL & Chrousos GP. Pharmacokinetic properties of the antiglucocorticoid and antiprogesterone steroid RU 486 in man. Journal of Pharmacology and Experimental Therapeutics 1987 241 401-406.
11. Sartor O & Cutler GB Jr. Mifepristone: treatment of Cushing's syndrome. Clinical Obstetrics and Gynecology 1996 39 506-510.
12. Bamberger CM & Chrousos GP. The glucocorticoid receptor and RU 486 in man. Annals of the New York Academy of Sciences 1995 761 296-310.
13. Cadepond F, Ulmann A & Baulieu EE. RU 486 (mifepristone): mechanisms of action and clinical uses. Annual Review of Medicine 1997 48 129-156.
14. Sitruk-Ware R & Spitz IM. Pharmacological properties of mifepristone: toxicology and safety in animal and human studies. Contraception 2003 68 409-420.
15. Raux-Demay MC, Pierret T, Bouvier D'yvoire M, Bertagna X & Girard F. Transient inhibition of RU 486 antiglucocorticoid action by dexamethasone. Journal of Clinical Endocrinology and Metabolism 1990 70 230-233.
16. Laue L, Chrousos GP. Loriaux DL, Barnes K, Munson P, Nieman L & Schaison G. The antiglucocorticoid. and antiprogestin steroid RU 486 suppresses the adrenocorticotropin response to ovine corticotropin releasing hormone in man. Journal of Clinical Endocrinology and Metabolism 1988 66 290-293.
17. Laue L, Gallucci W, Loriaux DL, Udelsman R & Chrousos GP. The antiglucocorticoid and antiprogestin steroid RU 486: its glucocorticoid agonist effect is inadequate to prevent adrenal insufficiency in primates. Journal of Clinical Endocrinology and Metabolism 1988 67 602-606.
18. Healy DL, Chrousos GP, Schulte HM, Williams RF, Gold PW, Baulieu EE & Hodgen GD. Pituitary and adrenal responses to the anti-progesterone and anti-glucocorticoid steroid RU 486 in primates. Journal of Clinical Endocrinology and Metabolism 1983 57 863-865.
19. Gaillard RC, Riondet A, Muller AF, Herrmann W & Baullieu EE. RU 486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day. PNAS 1984 81 3879-3882.
20. Lamberts SW, Koper JW & de Jong FH. The endocrine effects of long-term treatment with mifepristone (RU 486). Journal of Clinical Endocrinology and Metabolism 1991 73 187-191.
21. Garrel DR, Moussali R, de Oliveira A, Lesiege D & Lariviere F. RU 486 prevents the acute effects of cortisol on glucose and leucine metabolism. Journal of Clinical Endocrinology and Metabolism 1995 80 379-385.
22. Gaillard RC, Poffet D, Riondel AM & Saurat JH. RU 486 inhibits peripheral effects of glucocorticoids in humans. Journal of Clinical Endocrinology and Metabolism 1985 61 1009-1011.
23. Bertagna X, Escourolle H, Pinquier JL, Coste J, Raux-Demay MC, Perles P, Silvestre L, Luton JP & Strauch G. Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation. Journal of Clinical Endocrinology and Metabolism 1994 78 375-380.
24. Bertagna X, Bertagna C, Laudat MH, Husson JM, Girard F & Luton JP. Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 1986 63 639-643.
25. Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB, Merriam GR, Bardin CW & Loriaux DL. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. Journal of Clinical Endocrinology and Metabolism 1985 61 536-540.
26. Chrousos GP, Lane L, Nieman L, Udelsman R, Kawai S & Loriaux DL. Clinical Applications of RU 486, a Prototype Glucocorticoid and Progestin Antagonist New York: Raven Press, 19 89.
27. Chrousos GP. Laue L, Nieman LK, Kawai S, Udelsman RU, Brandon DD & Loriaux DL. Glucocorticoids and glucocorticoid antagonists: lessons from RU 486. Kidney International. Supplement 1988 26 S18-S23.
28. van der Lely AJ, Foeken K, Van Der Mast RC & Lamberts SW. Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486). Annals of Internal Medicine 1991 114 143-144.
29. Contreras P. Adrenal cancer: tumor regression with ketoconazole or mifepristone (RU 486). In vivo and in vitro evidence supporting tumoral hormone dependency. Proceedings of the 69th Annual Endocrine Society Meeting, Indianapolis, p 23, 1987.
30. Donckier JE, Michel LA, Berbinschi A, de Coster PM, de Plaen JF, Ketelslegers JM & Buysschaert M. Late recurrence of operated adrenocortical carcinoma: atrial natriuretic factor before and after treatment with mitotane. Surgery 1989 105 690-692.
31. Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR & Feldman D. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). Journal of Clinical Endocrinology and Metabolism 2001 86 3568-3573.
32. Newfield RS, Kalaitzoglou G, Licholai T, Chilton D, Ashraf J, Thompson EB & New MI. Normocortisolemic Cushing's syndrome initially presenting with increased glucocorticoid receptor numbers. Journal of Clinical Endocrinology and Metabolism 2000 85 14-21.
33. Newfield RS, Spitz IM, Isacson C & New MI. Long-term mifepristone (RU 486) therapy resulting in massive benign endometrial hyperplasia. Clinical Endocrinology 2001 54 399-404.
34. Beaufrere B, de Parscau L, Chatelain P, Morel Y, Aguercif M & Francois R. RU 486 administration in a child with Cushing's syndrome. Lancet 1987 2 217.
35. Goldberg JR, Plescia MG & Anastasio GD. Mifepristone (RU 486): current knowledge and future prospects. Archives of Family Medicine 1998 7 219-222.
36. Spitz IM & Bardin CW. Mifepristone (RU 486) - a modulator of progestin and glucocorticoid action. New England Journal of Medicine 1993 329 404-412.
37. Deraedt R, Vannier B & Fournex R. Toxicological study on RU 486. In: The Antiprogestin Steroid RU 486 and Human Fertility Control. pp 105-126, 1985. Eds EE Baulieu & SJ Segal, New York: Plenum Press 1992.
38. Koide SS. Mifepristone. Auxiliary therapeutic use in cancer and related disorders. Journal of Reproductive Medicine 1998 43 551-560.
39. Spitz rM, Grunberg SM, Chabbert-Bullet N, Lindenberg T, Gelber H & Sitruk-Ware R. Management of patients receiving long-term treatment with mifepristone. Fertility and Sterility 2005 84 1719-1726.
40. Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A & Sitruk-Ware R. Long-term administration of mifepristone (RU 486): clinical tolerance during extended treatment of meningioma. Cancer Investigation 2006 24 727-733.
41. Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA, Lucci L & Stevenson LL. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. Journal of Neurosurgery 1991 74 861-866.
42. de Keizer RJ & Smit JW. Mifepristone treatment in patients with surgically incurable sphenoid-ridge meningioma: a long-term follow-up. Eye 2004 18 954-958.
43. Eisinger SH, Bonfiglio, T, Fiscella K, Meldrum S & Guzick DS. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. Journal of Minimally Invasive Gynecology 2005 12 227-233.
44. Spitz IM. Progesterone antagonists and progesterone receptor modulators: an overview. Steroids 2003 68 981-993.
45. Chabbert-Buffet N, Meduri G, Bouchard P & Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Human Reproduction Update 2005 11 293-307.
46. Klijn JG, de Jong FH, Bakker GH, Lamberts SW, Rodenburg CJ & Alexieva-Figusch J. Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Research 1989 49 2851-2856.
47. Heikinheimo O, Ranta S, Grunberg S & Spitz IM. Alterations in sex steroids and gonadotropins in post-menopausal women subsequent to long-term mifepristone administration. Steroids 2000 65 831-836.
48. Murphy AA, Morales AJ, Kettel LM & Yen SS. Regression of uterine leiomyomata to the antiprogesterone RU 486: dose-response effect. Fertility and Sterility 1995 64 187-190.
49. Heikinheimo O, Ranta S, Grunberg S, Lahteenmaki P & Spitz IM. Alterations in the pituitary-thyroid and pituitary-adrenal axes - consequences of long-term mifepristone treatment. Metabolism 1997 46 292-296.
50. Laue L, Lotze MT, Chrousos GP, Barnes K, Loriaux DL & Fleisher TA. Effect of chronic treatment with the glucocorticoid antagonist RU 486 in man: toxicity, immunological, and hormonal aspects. Journal of Clinical Endocrinology and Metabolism 1990 71 1474-1480.